Dlx-5 Inhibitors
Dlx-5, a member of the Dlx family of homeobox transcription factors, plays a crucial role in embryonic development and tissue differentiation, particularly in the development of craniofacial structures, limbs, and central nervous system. It is prominently expressed in the developing forebrain, where it regulates the specification and patterning of various neuronal populations. Additionally, Dlx-5 is involved in the differentiation of mesenchymal cells into osteoblasts and chondrocytes, contributing to skeletal development and bone formation. Through its transcriptional activity, Dlx-5 controls the expression of genes involved in cell fate determination, proliferation, and differentiation, thereby exerting precise spatiotemporal control over developmental processes.
Inhibition of Dlx-5 function can occur through various mechanisms, disrupting its transcriptional activity and downstream signaling pathways. One common approach involves interfering with the binding of Dlx-5 to its target DNA sequences, thereby hindering the initiation of gene transcription. This can be achieved through the use of small molecules or peptides that competitively inhibit the interaction between Dlx-5 and its DNA-binding sites. Alternatively, inhibition may target upstream regulators or cofactors that modulate the activity of Dlx-5, such as coactivators or corepressors. By disrupting these interactions, the overall transcriptional activity of Dlx-5 can be attenuated, leading to downstream effects on gene expression patterns and cellular differentiation processes. Additionally, post-translational modifications of Dlx-5, such as phosphorylation or acetylation, can regulate its stability and activity, providing further avenues for inhibition. Overall, inhibition of Dlx-5 function represents a strategy for modulating developmental processes and may have implications for interventions targeting craniofacial abnormalities or skeletal disorders.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
HPI-4 | 302803-72-1 | sc-358720 sc-358720A | 5 mg 25 mg | $133.00 $530.00 | ||
HPI-4, a synthetic compound, acts as a direct inhibitor of Dlx-5 by binding to its DNA-binding domain, preventing its interaction with target DNA sequences. This interference inhibits the transcriptional activity of Dlx-5, leading to the downregulation of target genes involved in skeletal development. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a synthetic compound, acts as an indirect inhibitor of Dlx-5 by inhibiting the JNK signaling pathway. Inhibition of JNK signaling leads to decreased phosphorylation and activation of Dlx-5, resulting in the downregulation of target genes involved in skeletal development. The inhibition of JNK signaling by SP600125 illustrates its specific mechanism for indirectly inhibiting Dlx-5 and its downstream effects on skeletal gene expression and development. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $198.00 $650.00 | 16 | |
A83-01, a synthetic small molecule, serves as an indirect inhibitor of Dlx-5 by inhibiting the TGF-β signaling pathway. Inhibition of TGF-β signaling leads to decreased activation of Dlx-5, resulting in the downregulation of target genes involved in skeletal development. The inhibition of TGF-β signaling by A83-01 illustrates its specific mechanism for indirectly inhibiting Dlx-5 and its downstream effects on skeletal gene expression and development. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
Also called LDN-193189, this compound is a synthetic small molecule, acts as an indirect inhibitor of Dlx-5 by inhibiting the BMP signaling pathway. Inhibition of BMP signaling leads to decreased activation of Dlx-5, resulting in the downregulation of target genes involved in skeletal development. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542, a synthetic small molecule, serves as an indirect inhibitor of Dlx-5 by inhibiting the TGF-β signaling pathway. Inhibition of TGF-β signaling leads to decreased activation of Dlx-5, resulting in the downregulation of target genes involved in skeletal development. The inhibition of TGF-β signaling by SB431542 illustrates its specific mechanism for indirectly inhibiting Dlx-5 and its downstream effects on skeletal gene expression and development. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
XAV-939, a synthetic small molecule, acts as an indirect inhibitor of Dlx-5 by inhibiting the Wnt/β-catenin signaling pathway. Inhibition of Wnt/β-catenin signaling leads to decreased activation of Dlx-5, resulting in the downregulation of target genes involved in skeletal development. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $209.00 $352.00 | 3 | |
LY2157299 (Galunisertib), a synthetic small molecule, serves as an indirect inhibitor of Dlx-5 by inhibiting the TGF-β signaling pathway. Inhibition of TGF-β signaling leads to decreased activation of Dlx-5, resulting in the downregulation of target genes involved in skeletal development. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
BML-275 (Dorsomorphin), a synthetic small molecule, acts as an indirect inhibitor of Dlx-5 by inhibiting the BMP signaling pathway. Inhibition of BMP signaling leads to decreased activation of Dlx-5, resulting in the downregulation of target genes involved in skeletal development. The inhibition of BMP signaling by Dorsomorphin illustrates its specific mechanism for indirectly inhibiting Dlx-5 and its downstream effects on skeletal gene expression and development. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $37.00 $77.00 $184.00 $510.00 $1224.00 $5814.00 | 8 | |
Niclosamide, an approved anthelmintic drug, serves as an indirect inhibitor of Dlx-5 by modulating the Wnt/β-catenin signaling pathway. It promotes the degradation of β-catenin, leading to reduced activation of Dlx-5 and downregulation of target genes involved in skeletal development. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
LDN-214117, a synthetic small molecule, acts as an indirect inhibitor of Dlx-5 by inhibiting the BMP signaling pathway. Inhibition of BMP signaling leads to decreased activation of Dlx-5, resulting in the downregulation of target genes involved in skeletal development. The inhibition of BMP signaling by LDN-214117 illustrates its specific mechanism for indirectly inhibiting Dlx-5 and its downstream effects on skeletal gene expression and development. | ||||||